Clinical trials: Pancreatic Tumor
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Pancreatic Ductal Adenocarcinoma
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer.
- Trial name
- NCT01962909
- Testing
- PTP-01
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Virginia
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Advanced Pancreatic Cancer
The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.
- Trial name
- NCT05438797
- Testing
- Adoptive TIL-TCM transfer therapy
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Sizhen Wang
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
- Trial name
- NCT02948946
- Testing
- NETest
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Neoplasms
Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer
- Trial name
- NCT05681390
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Neuroendocrine Tumor, Carcinoid Tumor
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00942682
- Testing
- Sorafenib, RAD001
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Carcinoma
L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .
- Trial name
- CARPAN (NCT01330823)
- Testing
- L-Carnitine
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- University Medicine Greifswald
Pancreatic Cancer, Liver Metastases
CE-IOUS for Patients With Pancreatic Cancer Undergoing Surgery: A Prospective, Proof-of-concept Trial
BACKGROUND: Pancreatic Cancer (PC) is one of the leading cancer-related causes of death worldwide, with the majority of patients undergoing potentially curative surgery.
- Trial name
- NCT04683497
- Testing
- Contrast-enhanced Intraoperative Ultrasound
- Volunteers
- 50 people
- Sponsor
- University of Thessaly
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Metastatic Pancreatic Cancer
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease.
- Trial name
- NCT04820179
- Testing
- Cabozantinib + Atezolizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Arizona
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be…
- Conditions
- Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
- Trial name
- NCT03373188
- Testing
- Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Pancreatic Cyst, Pancreas Disease
Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
Bio-repository to collect bio-specimens from patients with 1) pancreatic cysts and 2) patients at high risk, defined by family history and/or genetic mutations, for pancreatic cancer.
- Trial name
- NCT03260842
- Testing
- Bio-Specimen Collection
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Stanford University
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing…
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
- Trial name
- NCT00093782
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms, Pancreatitis, Chronic
Magnetic Compressive Technique for Pancreatic Intestinal Anastomosis
In recent five years, the investigators have successfully developed different types of magnets and utilized in biliojejunostomy, concomitant biliojejunostomy and pancreaticojejunostomy during Whipple.
- Trial name
- MCTPIA (NCT03780946)
- Testing
- Magnetic anastomosis for pancreaticojejunostomy, Traditional hand-sewn anastomosis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pancreatic Cancer
SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has became a promising anti-cancer drug.
- Trial name
- CISPD-2 (NCT03716596)
- Testing
- SBRT, anti-PD-1 antibody
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
- Trial name
- NCT00316420
- Testing
- Capecitabine (Xeloda), Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.